Viral vectors as tools to model and treat neurodegenerative disorders
Identifieur interne : 000153 ( France/Analysis ); précédent : 000152; suivant : 000154Viral vectors as tools to model and treat neurodegenerative disorders
Auteurs : N. Déglon [France] ; P. Hantraye [France]Source :
- The Journal of Gene Medicine [ 1099-498X ] ; 2005-05.
English descriptors
Abstract
The identification of disease‐causing genes in familial forms of neurodegenerative disorders and the development of genetic models closely replicating human central nervous system (CNS) pathologies have drastically changed our understanding of the molecular events leading to neuronal cell death. If these achievements open new opportunities of therapeutic interventions, including gene‐based therapies, the presence of the blood‐brain barrier and the post‐mitotic and poor regenerative nature of the target cells constitute important challenges. Efficient delivery systems taking into account the specificity of the CNS are required to administer potential therapeutic candidates. In addition, genetic models in large animals that replicate the late stages of the diseases are in most cases not available for pre‐clinical studies. The present review summarizes the potential of viral vectors as tools to create new genetic models of CNS disorders in various species including primates and the recent progress toward viral gene therapy clinical trials for the administration of therapeutic candidates into the brain. Copyright © 2005 John Wiley & Sons, Ltd.
Url:
DOI: 10.1002/jgm.707
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: 002F99
- to stream Main, to step Curation: 002C08
- to stream Main, to step Exploration: 001391
- to stream France, to step Extraction: 000153
Links to Exploration step
ISTEX:400C237FF12A4FA962BB0FF198975ACC48BF84EDLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Viral vectors as tools to model and treat neurodegenerative disorders</title><author><name sortKey="Deglon, N" sort="Deglon, N" uniqKey="Deglon N" first="N." last="Déglon">N. Déglon</name></author><author><name sortKey="Hantraye, P" sort="Hantraye, P" uniqKey="Hantraye P" first="P." last="Hantraye">P. Hantraye</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:400C237FF12A4FA962BB0FF198975ACC48BF84ED</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/jgm.707</idno><idno type="url">https://api.istex.fr/document/400C237FF12A4FA962BB0FF198975ACC48BF84ED/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002F99</idno><idno type="wicri:Area/Main/Curation">002C08</idno><idno type="wicri:Area/Main/Exploration">001391</idno><idno type="wicri:Area/France/Extraction">000153</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Viral vectors as tools to model and treat neurodegenerative disorders</title><author><name sortKey="Deglon, N" sort="Deglon, N" uniqKey="Deglon N" first="N." last="Déglon">N. Déglon</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Commissariat à l'Energie Atomique (CEA) CNRS URA2210, Service Hospitalier Frédéric Joliot and ImaGene Program, Orsay Cedex</wicri:regionArea><wicri:noRegion>Orsay Cedex</wicri:noRegion><wicri:noRegion>Orsay Cedex</wicri:noRegion></affiliation></author><author><name sortKey="Hantraye, P" sort="Hantraye, P" uniqKey="Hantraye P" first="P." last="Hantraye">P. Hantraye</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Commissariat à l'Energie Atomique (CEA) CNRS URA2210, Service Hospitalier Frédéric Joliot and ImaGene Program, Orsay Cedex</wicri:regionArea><wicri:noRegion>Orsay Cedex</wicri:noRegion><wicri:noRegion>Orsay Cedex</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">The Journal of Gene Medicine</title><title level="j" type="sub">A cross‐disciplinary journal for research on the science of gene transfer and its clinical applications</title><title level="j" type="abbrev">J. Gene Med.</title><idno type="ISSN">1099-498X</idno><idno type="eISSN">1521-2254</idno><imprint><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2005-05">2005-05</date><biblScope unit="volume">7</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="530">530</biblScope><biblScope unit="page" to="539">539</biblScope></imprint><idno type="ISSN">1099-498X</idno></series><idno type="istex">400C237FF12A4FA962BB0FF198975ACC48BF84ED</idno><idno type="DOI">10.1002/jgm.707</idno><idno type="ArticleID">JGM707</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1099-498X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Gene therapy</term><term>animal models</term><term>neurodegenerative diseases</term><term>viral vectors</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The identification of disease‐causing genes in familial forms of neurodegenerative disorders and the development of genetic models closely replicating human central nervous system (CNS) pathologies have drastically changed our understanding of the molecular events leading to neuronal cell death. If these achievements open new opportunities of therapeutic interventions, including gene‐based therapies, the presence of the blood‐brain barrier and the post‐mitotic and poor regenerative nature of the target cells constitute important challenges. Efficient delivery systems taking into account the specificity of the CNS are required to administer potential therapeutic candidates. In addition, genetic models in large animals that replicate the late stages of the diseases are in most cases not available for pre‐clinical studies. The present review summarizes the potential of viral vectors as tools to create new genetic models of CNS disorders in various species including primates and the recent progress toward viral gene therapy clinical trials for the administration of therapeutic candidates into the brain. Copyright © 2005 John Wiley & Sons, Ltd.</div></front></TEI><affiliations><list><country><li>France</li></country></list><tree><country name="France"><noRegion><name sortKey="Deglon, N" sort="Deglon, N" uniqKey="Deglon N" first="N." last="Déglon">N. Déglon</name></noRegion><name sortKey="Hantraye, P" sort="Hantraye, P" uniqKey="Hantraye P" first="P." last="Hantraye">P. Hantraye</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000153 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000153 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:400C237FF12A4FA962BB0FF198975ACC48BF84ED
|texte= Viral vectors as tools to model and treat neurodegenerative disorders
}}
| This area was generated with Dilib version V0.6.23. |  |